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Abstract Chronic granulomatous disease (CGD) is phago-
cytic cell metabolic disorder resulting in recurrent infec-
tions and granuloma formation. This paper reports the
favourable outcome of allogeneic transplantation in six
high-risk CGD patients. The following donors were used:
HLA-matched, related (two) and unrelated (three), and
HLA-mismatched, unrelated (one). One patient was trans-
planted twice using the same sibling donor because of graft
rejection at 6 months after reduced-intensity conditioning
transplant (fludarabine and melphalan). Myeloablative
conditioning regimen consisted of busulphan and cyclo-
phosphamide. Stem cell source was unmanipulated bone
marrow containing: 5.2 (2.6–6.5)×10
8 nucleated cells, 3.8
(2.0–8.0)×10
6 CD34+ cells and 45 (27–64)×10
6 CD3+
cells per kilogramme. Graft-versus-host disease prophylaxis
consisted of cyclosporine A and, for unrelated donors, short
course of methotrexate and anti-T-lymphocyte globulin.
Mean neutrophile and platelet engraftments were observed
at day 22 (20–23) and day 20 (16–29), respectively. Pre-
existing infections and inflammatory granulomas resolved.
With the follow-up of 4–35 months (mean, 20 months), all
patients are alive and well with full donor chimerism and
normalized superoxide production.
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Introduction
Chronic granulomatous disease (CGD) is X-linked or
autosomal recessive inherited immune deficiency caused
by mutations in the genes encoding the various subunits of
the NADPH oxidase system of phagocytic cells responsible
for the killing of phagocytosed microorganisms. CGD
occurs with an estimated frequency of one in 250,000 live
births. This defect is associated with significant morbidity
and mortality so the predicted life expectancy is of about
25–30 years of age. The disease is characterized by
recurrent, severe and life-threatening, bacterial and fungal
infections with granuloma formation in different organs [1].
Usual sites of infections, mainly caused by catalase-
positive microorganisms (e.g. Aspergillus sp., Staphylococ-
cus sp., Salmonella sp.), are lungs, skin, gastrointestinal
tract, liver and lymph nodes. Persistent inflammatory
reaction to infection may lead to colitis with subsequent
growth failure, gastric outlet obstruction, lung disease and
granuloma formation [2, 3].
Conventional management for patients with CGD consists
of lifelong anti-infectious prophylaxis with cotrimoxazole or
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roids and/or interferon-γ (IFN-γ). Nevertheless, the
annual mortality is still 2–5%, and only 50% of patients
are alive at 30 years [4, 5]. Therefore, there is a need for
more effective therapies. Allogeneic haematopoietic stem
cell transplantation (HSCT) is the only curative treatment
for CGD with the excellent outcome noted in patients
asymptomatic at transplantation. In a high-risk group of
CGD patients (adults with organ dysfunction and/or
patients with active inflammation and infections), the
transplant-related mortality (TRM) about 30% is noted
[6, 7].
Here, we report on six young CGD patients successfully
treated with allogeneic HSCT with full correction of the
phagocytic function before onset of organ dysfunction due
to chronic inflammation.
Patients and Methods
Patient 1, a 2-year-old boy, was diagnosed at the age of
1.5 years to have X-linked CGD. He presented with
recurrent lymphadenopathy, pneumonia, diarrhoea and skin
infection. On admission, the generalized lymphadenopathy,
mild hepatomegaly and multiple granulomas of the lungs
were observed.
Patient 2, a 13-year-old girl, was diagnosed as having
CGD at the age of 2 years. In the past, she had Salmonella
Typhimurium gastroenteritis, recurrent lymphadenopathy,
cervical abscess, sinusitis with Aspergillus fumigatus,
frequent pneumonias, sepsis, herpes and varicella infections
and multiple skin infections. She was admitted to our
department before transplantation with sinusitis due to
aspergillosis despite intensive antifungal treatment (ampho-
tericin B and voriconasole).
Patient 3, a 5-year-old boy, was diagnosed with CGD at
the age of 10 months after surgical removal of multiple
abscesses of lymph nodes. His mother’s older brother and
her first son died of severe infections in early childhood. He
has been repeatedly hospitalized with skin abscesses,
meningitis, gastroenteritis (Salmonella Typhimurium) and
severe pneumonias.
Patient 4, a 3.5-year-old boy with X-linked CGD
(Xp21.1, subtype X91+), was diagnosed 6 months ago.
The family history indicated that his mother’s brother died
at the age of 3 years because of infection. The patient
experienced recurrent lung and skin infections. The CT
abdominal scan performed at the age of 3 years due to fever
and abdominal pain showed hepatomegaly with multiple
nodular areas.
Patient 5, a 1.5-year-old boy, was diagnosed with X-linked
CGD at the age of 6 months. He had in the past sinusitis,
kidney, liver abscess and multiple skin infections.
Patient 6, a 2-yeard old boy with CGD, was diagnosed
6 months ago after serious gastroenterocolitis (Salmonella
Typhimurium). This boy is a cousin of patient 3.
Diagnosis
In all patients, the diagnosis of CGD was established on the
basis of clinical symptoms and the lack of chemilumines-
cence response to latex stimulation of blood measurement
as described previously [8] and confirmed by nitroblue
tetrazolium (NBT) reduction test [9].
Prophylaxis and Treatment
The antibacterial and antimycotic treatment or prophylaxis
was introduced immediately after diagnosis of CGD and
continued until transplantation.
Transplantation
The stem cell transplantation and collection of data before
treatment were performed after written informed consent of
parents and patient 2. The information on the beneficial
effects of conventional antibacterial/antifungal prophylaxis/
treatment, the risk of allografting, especially in the presence
of overt infections or inflammatory symptoms, and a lack
of sibling donors was also provided. Donor and recipient
HLA matching was performed by molecular typing of HLA
classes I (A, B, Cw) and II loci (DRB1, DQB1). Patients 1
and 6 underwent bone marrow transplantation from a
sibling donor with HLA-identical genotype. Patients 2, 4
and 5 received HLA-identical bone marrow from unrelated
donors, and patient 3 was transplanted with bone marrow
from mismatched unrelated donor [patient’sH L A :
A*0201*2402, B*3906*4402, Cw*0702*0704,
DRB1*1601, DQ*0502; donor’s HLA: A*0201*2402,
B*3901*4402, Cw*1203*0704, DRB1*1601, DQ*0502].
The characteristics of patients and donors are shown in
Table I. Patients were nursed in a high-efficiency, particle-
air-filtered protected environment. During transplantation
period, leucocyte-depleted and irradiated blood products
were used. Colistin at 100,000 U/kg/day was given as an
oral gut decontamination. Prophylaxis regimen also includ-
ed cotrimoxazole, acyclovir, fluconazole, heparin and,
when needed, intravenous immunoglobulin (IVIG) substi-
tution until immune reconstitution. Patient 2 with fungal
sinusitis at transplantation was treated with voriconazole
and caspofungin until engraftment. Five of six patients
received busulphan-based myeloablative conditioning reg-
imen, combined with cyclophosphamide. Patient 1 was
conditioned according to reduced-intensity (RI) protocol
with the use of fludarabine and melphalan. Details of
conditioning regimens are shown in Table II. Stem cell
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(2.6–6.5)×10
8 nucleated cells (NS), 3.3 (2.0–4.9)×10
6
CD34+ cells and 44 (26–64)×10
6 CD3+ cells per kilo-
gramme of recipient body weight (b.w.). The cell doses for
patient transplanted with an RI were as follows: 3.0×10
8
NS, 4.0×10
6 CD34+ and 26×10
6 CD3+ cells per kilo-
gramme of body weight. Graft-versus-host disease (GvHD)
prophylaxis consisted of cyclosporine A (CsA) beginning
on day −1 (patients 1, 5 and 6) and on day −4 (patients 2, 3
and 4). The plasma level of CsA was maintained between
150 and 200 μg/mL, and this therapy was continued until
3 months (patients 1 and 6) and 6 months (patients 2, 3, 4
and 5). The CsA was tapered rapidly because of gradually
decreasing chimerism in patient 1 and slowly in patients 2,
Table I The characteristics of patients and donors
Type of donor Age (years) Gender CMV status EBV status Blood groups AB0 (Rh)
RDR D RDRDR D
Patient 1 MSD 2/3
a 6/7
a MF + + + + A ( −)A ( −)
Patient 2 MUD 13 26 F F − +++ 0 ( −) 0 (+)
Patient 3 MMUD 5 28 M F + − + + 0 (+) 0 (+)
Patient 4 MUD 4 21 M M − + − + A (+) A (−)
Patient 5 MUD 1 26 M F − + + + B (+) 0 (+)
Patient 6 MSD 2 12 M F + + + − 0 (+) B (+)
R recipient, D donor, CMV cytomegalovirus, EBV Epstein–Barr virus, MSD matched sibling donor, MUD matched unrelated donor, MMUD
mismatched unrelated donor, + positive, − negative
aAt second transplantation
Table II Conditioning regimens
Regimen Total dose Daily dose Administration Days
Patient 1 Flu 150 mg/m
2 30 mg/m
2 i.v. in 30 min −7, −6, −5, −4, −3
Mel 140 mg/m
2 70 mg/m
2 i.v. in 1 h −3, −2
Patient 1
a Bu 20 mg/kg 5 mg/kg p.o. q 6 h −9, −8, −7, −6
Cy 200 mg/kg 50 mg/kg i.v. in 1 h −5, −4, −3, −2
ATG
b 7.5 mg/kg 3.75 mg/kg i.v. in 8–10 h −3, −2
Patient 2 Bu 16 mg/kg 4 mg/kg p.o. q 6 h −9, −8, −7, −6
Cy 200 mg/kg 50 mg/kg i.v. in 1 h −5, −4, −3, −2
ATG
b 10 mg/kg 2.5 mg/kg i.v. in 8–10 h −4, −3, −2, −1
Patient 3 Bu 20 mg/kg 5 mg/kg p.o. q 6 h −7, −6, −5, −4
Cy 120 mg/kg 60 mg/kg i.v. in 1 h −3, −2
ATG
c 60 mg/kg 20 mg/kg i.v. in 8–10 h −3, −2, −1
Patient 4 Bu 20 mg/kg 5 mg/kg p.o. q 6 h −9, −8, −7, −6
Cy 200 mg/kg 50 mg/kg i.v. in 1 h −5, −4, −3, −2
ATG
c 60 mg/kg 20 mg/kg i.v. in 8–10 h −3, −2, −1
Patient 5 Bu 20 mg/kg 5 mg/kg p.o. q 6 h −9, −8, −7, −6
Cy 200 mg/kg 50 mg/kg i.v. in 1 h −5, −4, −3, −2
ATG
b 10 mg/kg 2.5 mg/kg i.v. in 8–10 h −3, −2, −1
Patient 6 Bu 20 mg/kg 5 mg/kg p.o. q 6 h −9, −8, −7, −6
Cy 200 mg/kg 50 mg/kg i.v. in 1 h −5, −4, −3, −2
Flu fludarabine, Mel melphalan, Bu busulphan, Cy cyclophosphamide, ATG rabbit anti-T-cell globulin
aAt second transplantation
bGenzyme
cFresenius
334 J Clin Immunol (2011) 31:332–3373, 4, 5 and 6. Additionally, patients transplanted from
unrelated donors received short course of methotrexate at
10 mg/m
2.
The chimerism was studied at +30, 100, 180 and
360 days after standard HSCT and every 1 month after
non-myeloablative transplantation by karyotyping (fluores-
cence in situ hybridization) or analysis of informative
microsatellite DNA sequences with the use of standard
techniques. Neutrophil function and NK-, T- and B-cell
reconstitution measurements were performed at the same
time schedule and then every year. Lymphocyte subsets
were measured by flow cytometry including CD3+, CD4+,
CD8+, CD19+ and CD16+56+ cells. The presence of
oxidase-positive neutrophils was detected by NBT tests.
Immunoglobulin levels (IgG, IgA, IgM) were measured by
nephelometry.
Results
Engraftment
Engraftment withfull chimerismandfunctioningneutrophiles
wereobservedinallpatients.Haemopoieticrecoveryoccurred
within a median time of 22 days (range, 20–23 days) to
neutrophile count >500/μL and within a median time of
20 days (range, 16–29 days) to platelet count >20,000/mL
(Table III). The donor-derived haemopoiesis and the normal
NBT reduction remained in five patients. In patient 1, after
initial engraftment, chimerism fell to 14% despite cessation
of CsA and donor lymphocyte infusion (DLI) in four
increasing doses every 4–6 weeks: first, 0.2×10
6/kg; second,
1.0×10
6/kg; third, 1.8×10
6/kg and fourth, 5.0×10
6/kg. In
this patient, after the first HSCT, the lymphadenopathy and
granulomas resolved despite of slow rejection. The second
transplant from the same sibling donor after myeloablative
conditioning was performed 8 months after the first HSCT
(Table II). Unmanipulated bone marrow containing, per
kilogramme of recipient b.w., 6.0×10
8 NS, 8.0×10
6 CD34+
cells and 53×10
6 CD3+ cells was infused. Neutrophil
engraftment occurred on day +23 and platelets on day +29
(Table III). Full donor chimerism and normal value of NBT
test were observed on day +30.
Survival
There was no episode of serious conditioning-related
toxicity. For patients 1, 2, 4, 5 and 6, transfusion
requirement was low, with median of 2 (range, 1–3) red
blood cell concentrates and median of 4 (range, 3–7) of
platelet transfusions. Patient 3 received eight red blood cell
and six platelet concentrates because of haemorrhagic
diarrhoea due to acute GvHD (aGvHD). He had also
rotavirus infection and cytomegalovirus reactivation treated
with gancyclovir with good response. No febrile episodes
or exacerbations of preexisting infections were observed.
The median length of hospitalization was 36 days (range,
33–61 days). In patient 2, the short episode of haemor-
rhagic cystitis grade II was observed at 3 months after
transplantation but resolved after symptomatic therapy. All
patients are alive and well with a median follow-up of
20 months (range, 4–35 months) after HSCT. In all patients,
the lymphadenopathy and granulomas resolved and therapy
of refractory pre-existing infections is not required.
Graft-Versus-Host Disease
Two patients had symptoms of aGvHD. Patient 2 presented
with mild aGvHD (increasing level of bilirubin and AAT)
with good response to steroids. Patient 3 developed severe
grade IV acute GvHD with the gut, liver and skin
involvement that required therapy with prednisolone,
mycophenolate mofetil, tacrolimus and oral budezonide,
and which finally resolved after anti-TNF-α therapy
Table III Engraftment and chimerism
Engraftment (day after HSCT) NBT Donor’s chimerism
Neutrophil >500/μL PLT >20/μL +30 day (N, >0.1) +30 days (%) +100 days (%) +180 days (%) +1 year (%)
Patient 1 22 – 0.154 100 37 14 –
Patient 1
a 23 29 0.226 100 100 100 100
Patient 2 20 17 0.318 100 100 100 100
Patient 3 21 21 0.207 100 100 100 100
Patient 4 22 18 0.218 100 100 100 100
Patient 5 22 16 0.315 100 100 ––
Patient 6 21 29 0.143 100 100 ––
HSCT haematopoietic stem cell transplantation, PLT platelets, NBT nitroblue tetrazolium test, N normal value
aAt second transplantation
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6/
kg). Again, the limited chronic GVHD of skin developed
but gradually responded to treatment without continuing
sequelae.
Immunological Reconstitution
Since engraftment, all patients demonstrated normal NBT
test. The IVIG replacement therapy was discontinued
shortly after transplantation. Patients transplanted from
unrelated donors showed subnormal count of lymphocyte
T, B and NK cells during first year after HSCT. The
normalization of lymphocyte number was faster in patient
transplanted from matched related donor. All patients were
included in revaccination protocol according to our sched-
ule [10, 11]. In patients 1 and 2, the basic programme of
vaccination against tetanus, diphtheria and hepatitis B virus
was completed. Antibody production against these patho-
gens was adequate.
Discussion
CGD has been extensively studied during the last years.
Because gene therapy is still in its infancy, allogeneic
HSCT remains the only curative therapy for CGD. The
benefits of HSCT like normal growth and improvement in
quality of life with no need for medication are clear. This is
in contrast to non-transplanted patients who remain on
lifelong antimicrobial prophylaxis, with a continued risk of
infections resistant to the prophylactic treatment that require
frequent hospitalization [5, 12].
Although the first reports of transplantation in CGD
were not so optimistic, the use of matched sibling donor
improved the survival (above 90%) especially in children
without severe infections and at an early stage of disease.
As the chance of finding a matched related donor is less
than 25%, and haploidentical HSCT is considered as a high
risk due to delayed immune reconstitution and graft failure,
the unrelated donor transplantation has been established as
an alternative procedure [13]. However, the use of unrelated
donor could be associated with a higher risk of complica-
tions after HSCT [14].
In our study, four patients underwent transplantation
from unrelated donors (three matched and one mis-
matched). This mismatched unrelated donor was used in
situation of a serious clinical status of the recipient and after
four years of unsuccessfully searching for a matched
unrelated donor. Finally, the decision of mismatched donor
HSCT was regarded as a life-saving procedure.
The EBMT advocated myeloablative regimens, mostly
consisting of busulphan and cyclophosphamide allografts
from HLA-matched related donors, which provided excel-
lent results in low-risk CGD patients [15, 16]. In opinion of
other researchers, the myeloablative conditioning was
associated with the high rates of severe acute GVHD and
pulmonary infections leading to the TRM of above 30%
especially in advanced CGD patients with active inflam-
mation or infections [6, 17].
The therapeutic option of allogeneic transplantation after
reduced-intensity conditioning (RIC) may be the alternative
for CGD patients with coexisting severe infections and
organ damage [18, 19]. However, the RIC regimens
performed until now have shown a significant risk of
incomplete engraftment with the donor haematopoietic cells
or graft rejection and GvHD, particularly if DLI has to be
used to ensure engraftment. Nevertheless, the RIC HSCT is
usually enough to improve clinical status and resolve the
inflammation and infections before the graft rejection [20–
22]. Moreover, additional standard myeloablative HSCT
could be performed as a salvage therapy if second
transplant is required [23].
In the present group, patient 1 was transplanted twice
from the HLA-identical sibling. The first time was with
RIC and subsequently with myeloablative conditioning.
After transplantation with RIC, the graft rejection
occurred and donor’s chimerism decreased from 100%
to 14% within 6 months despite withdrawal of immuno-
suppression and DLI. The subsequent transplantation led
to a rapid engraftment. Five remaining patients who
received myeloablative HSCT donors engrafted around
22 days after transplantation, and the stable full donor
chimerism and normal phagocyte function were observed
at 30 days.
In our opinion, for patients with CGD, the optimal time
of transplantation is critical. In most cases of CGD, HSCT
is postponed until the patient is chronically ill. However, if
transplantation is delayed, the chances of severe infections,
the risk of GVHD and other serious transplant complica-
tions significantly increase [6].
The severe GVHD remains a special risk in CGD
patients, possibly because CGD phagocytes have a specific
propensity for increased production of TNF-α. Moreover,
its level significantly rose in patients with granulomatous
colitis or aspergillosis. Therefore, TNF-antagonist therapy
may be beneficial if given as early treatment for GVHD and
other complications [24, 25].
All presented patients are now judged as cured by
clinical status and phagocytic function. No conditioning
toxicity was observed despite the use of myeloablative
regimens.
We believe that it is desirable to perform HSCT in young
patients with proven diagnosis of CGD before the onset of
life-threatening infections and organ damage due to chronic
inflammation. As the HSCT procedure is safe enough, it
may challenge the common view that HSCT is indicated in
336 J Clin Immunol (2011) 31:332–337CGD patients only after severe clinical episode confirming
the diagnosis.
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